LLY

1,015.94

-0.68%↓

JNJ

194.16

-0.04%↓

ABBV

232.14

-1.25%↓

UNH

326.22

-2.02%↓

AZN

88.54

+0.6%↑

LLY

1,015.94

-0.68%↓

JNJ

194.16

-0.04%↓

ABBV

232.14

-1.25%↓

UNH

326.22

-2.02%↓

AZN

88.54

+0.6%↑

LLY

1,015.94

-0.68%↓

JNJ

194.16

-0.04%↓

ABBV

232.14

-1.25%↓

UNH

326.22

-2.02%↓

AZN

88.54

+0.6%↑

LLY

1,015.94

-0.68%↓

JNJ

194.16

-0.04%↓

ABBV

232.14

-1.25%↓

UNH

326.22

-2.02%↓

AZN

88.54

+0.6%↑

LLY

1,015.94

-0.68%↓

JNJ

194.16

-0.04%↓

ABBV

232.14

-1.25%↓

UNH

326.22

-2.02%↓

AZN

88.54

+0.6%↑

Kodu・Aktsiate loetelu・Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals Inc

Suletud

1.21 -7.63

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.21

Max

1.31

Põhinäitajad
By Trading Economics
Sissetulek	9.1M -6.9M
Kasumimarginaal	-821.235
Töötajad	27
EBITDA	9.1M -7.5M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+361.54% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	19. nov 2025

Turustatistika
By TradingEconomics
Turukapital	-10M 41M
Eelmine avamishind	8.84
Eelmine sulgemishind	1.21

Actinium Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

13. nov 2025, 21:34 UTC

Tulu

Applied Materials 4Q Sales Fall; Forecasts Higher Demand in 2H26

13. nov 2025, 23:45 UTC

Market Talk

Nikkei May Fall After Wall Street's Weakness -- Market Talk

13. nov 2025, 23:42 UTC

Omandamised, ülevõtmised, äriostud

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 4th Update

13. nov 2025, 23:41 UTC

Market Talk

Gold Edges Higher on Possible Dip-Buying -- Market Talk

13. nov 2025, 23:24 UTC

Tulu

JBS NV: Robust U.S. Beef Demand Supported 3Q North America Sales >JBS

13. nov 2025, 23:24 UTC

Tulu

JBS NV: Live Cattle Prices Have Remained High, Pressuring Profitability >JBS

13. nov 2025, 23:23 UTC

Tulu

JBS NV 3Q EPS 52c >JBS

13. nov 2025, 23:23 UTC

Tulu

JBS NV 3Q Sales $22.6B >JBS

13. nov 2025, 23:04 UTC

Market Talk

RBA Looks Set To Remain Sidelined For a While Yet -- Market Talk

13. nov 2025, 22:02 UTC

Tulu

Nu Holdings 3Q Net $783M >NU

13. nov 2025, 22:01 UTC

Tulu

Nu Holdings 3Q Rev $4.2B >NU

13. nov 2025, 21:51 UTC

Omandamised, ülevõtmised, äriostud

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 3rd Update

13. nov 2025, 21:50 UTC

Tulu

Disney Posts Roughly Flat Quarterly Revenue as TV Declines Continue -- 4th Update

13. nov 2025, 21:45 UTC

Omandamised, ülevõtmised, äriostud

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 2nd Update

13. nov 2025, 21:41 UTC

Omandamised, ülevõtmised, äriostud

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- Update

13. nov 2025, 21:36 UTC

Omandamised, ülevõtmised, äriostud

Paramount Plans to Bid for All of Warner Bros., Sources Say -- WSJ

13. nov 2025, 21:36 UTC

Omandamised, ülevõtmised, äriostud

Paramount, Comcast, Netflix Among Potential Bidders That Have Looked at Warner Bros. Financials, Sources Say -- WSJ

13. nov 2025, 21:36 UTC

Omandamised, ülevõtmised, äriostud

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- WSJ

13. nov 2025, 21:36 UTC

Omandamised, ülevõtmised, äriostud

Netflix, Comcast Each Considering Pursuing Warner Bros. Studio, Streaming Assets, Sources Say -- WSJ

13. nov 2025, 21:36 UTC

Omandamised, ülevõtmised, äriostud

Bids for Warner Bros. Discovery Due Next Week, Sources Say -- WSJ

13. nov 2025, 21:33 UTC

Market Talk

Banks See CAD Appreciation Through 2026, Trade Poses 'Clear' Risk -- Market Talk

13. nov 2025, 21:33 UTC

Tulu

If Investors Like Rocket Lab Stock, They Should Love Firefly Shares -- Barrons.com

13. nov 2025, 21:31 UTC

Tulu

Applied Materials Stock Falls Despite Strong Earnings -- Barrons.com

13. nov 2025, 21:25 UTC

Tulu

Figure Tech Solutions 3Q Rev $156.4M >FIGR

13. nov 2025, 21:25 UTC

Tulu

Figure Tech Solutions 3Q EPS 34c >FIGR

13. nov 2025, 21:23 UTC

Tulu

Intchains Group 3Q Rev $1.3M >ICG

13. nov 2025, 21:03 UTC

Tulu

Applied Materials Sees 1Q Rev $6.35B-$7.35B >AMAT

13. nov 2025, 21:02 UTC

Tulu

Applied Materials Sees 1Q Adj EPS $1.98-Adj EPS $2.38 >AMAT

13. nov 2025, 21:01 UTC

Tulu

Applied Materials 4Q Rev $6.8B >AMAT

13. nov 2025, 21:01 UTC

Tulu

Applied Materials 4Q Gross Margin 48.0% >AMAT

Võrdlus sarnastega

Hinnamuutus

Actinium Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

361.54% tõus

12 kuu keskmine prognoos

Keskmine 6 USD 361.54%

Kõrge 9 USD

Madal 4 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Actinium Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Actinium Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.